Participated · Equity · Nov 2017

Saina Biotech, founded by a team including Peking University academician Xie Xiaoliang, Professor Huang Yanyi and Dr. Chen Zitian, is a high-tech company integrating gene-technology R&D, translation, production and sales. The company holds more than a hundred Chinese and PCT patents, with core patents authorized in the United States, and centers its technology on two proprietary sequencing innovations: Fluorogenic signal generation and error-correcting coding (ECC). It operates complete manufacturing and R&D capabilities including chemical and enzyme raw-material bases, a GMP reagent production workshop, an instrument factory, and optical, fluidics and algorithm teams. Based on this platform Saina launched the S100 sequencing system, a high-throughput, dual-mode, fast and accurate platform designed for flexible deployment and to meet domestic clinical needs for small samples, speed and low cost. In June 2022 the S100 instrument and companion reagent kits received EU CE-IVDR certification, clearing the way for sales in the European market. The company says it will continue next-generation sequencing R&D, accelerate S100 commercialization and build a China-led sequencing ecosystem to support national bioinformation security. SainaBio develops and industrializes high-throughput gene sequencing platforms, proprietary chips, and reagents aimed at clinical disease detection, diagnosis, and screening. Its core sequencing technologies—Fluorogenic emission and error-correcting ECC coding—were developed by teams led by prominent scientists including Prof. Xie Xiaoliang and Prof. Huang Yanyi. The company reports a multidisciplinary team of nearly 100 technical staff, with more than one-third of R&D personnel holding doctoral or master’s degrees and an instrument engineering team drawn from top domestic IVD firms. SainaBio has completed研发 and validation of its core technologies and produced a first-generation prototype that the company says matches or exceeds comparable international machines on cost, accuracy, and speed. The firm received a Beijing Municipal Science & Technology Commission project approval in September 2017. Proceeds from the recent financing will be used to finalize clinical registration, optimize and industrialize prototypes, scale instrument and chip production, and support product market entry.

Participated · Equity · Apr 2013

Vidyo offers the VidyoWorks software platform and APIs that embed real-time video, audio and content communication into clinical workflows and consumer-facing applications. The platform includes a FIPS 140-2 certified crypto-kernel providing HIPAA-compliant encryption and is used by enterprise customers, service providers, and ecosystem partners. Vidyo’s technology powers telehealth applications for more than 40% of the top 100 Integrated Delivery Networks in the U.S. and is integrated with major EHR systems and a wide set of healthcare workflow tools. The company reports millions of users connecting daily and holds over 110 patents. Vidyo plans to use the latest funding to accelerate growth in vertical markets and expand its healthcare deployments. Vidyo offers the VidyoWorks platform and APIs, leveraging Scalable Video Coding (SVC) and the patented VidyoRouter to deliver scalable video conferencing and integration into workflows and devices. The company supplies video infrastructure and products such as VidyoRoom systems and personal telepresence for markets including banking, healthcare, government and enterprise. Vidyo reports deployments with capacity exceeding hundreds of millions of minutes per year in some networks and more than 1,200 VidyoRoom systems in others. It holds more than 60 patents issued and patents pending across 65 patent families. Vidyo positions its technology to enable integration of visual communications into electronic medical records and new connected devices, targeting broader adoption as the Internet of Things expands. The company will use newly raised funds for sales and market development to broaden adoption of the VidyoWorks platform. Vidyo develops software-based video conferencing that lets customers use existing room systems (Cisco, Polycom, Lifesize, H.323/SIP), Microsoft Lync clients, and mobile devices. Its approach targets lower-cost alternatives to hardware-based incumbents and supports virtualized deployments on off-the-shelf equipment. The company reported year-over-year billings growth of 68% in 2012, with sales up 77% in both healthcare and education verticals. Vidyo has more than 250 employees across 13 global offices and holds 26 issued patents with 56 pending. With the new funding, the company plans to continue growing its engineering team and expand worldwide, and it recently struck a distribution deal with education consortium Internet2. Vidyo builds video conferencing software that uses H.264 Scalable Video Coding (SVC) to deliver high-quality calls even on constrained mobile networks. It sells some conferencing equipment directly to enterprises and has a large and growing OEM licensing business with partners including Google, Ricoh and Hitachi. The company announced a strategic investment from Juniper Networks via the Junos Innovation Fund; terms of that investment were not disclosed. The Juniper investment could foreshadow a closer partnership or a possible acquisition and potential integration of Vidyo’s technology into Juniper networking equipment. Vidyo is headquartered in Hackensack, New Jersey, operates 12 other offices and has about 225 employees. Since its founding in 2005 the company has raised about $100 million in total funding. Vidyo pioneers personal telepresence with a software-based communication and collaboration platform that spans immersive rooms, desktops, tablets and smartphones. Its VidyoRouter is built on a patented Adaptive Video Layering architecture that leverages H.264 Scalable Video Coding to eliminate the MCU and provide error resiliency, low latency and rate matching over Internet, LTE, 3G and 4G networks. The platform includes gateways that interoperate with H.323 and SIP endpoints and supports cloud-based broadcast solutions. Vidyo holds 9 awarded patents and has 27 patents pending, and has received industry recognition including Best of Interop, Frost & Sullivan and Wall Street Journal honors. The company plans to use the new funding to expand sales and marketing globally to address demand for flexible, scalable telepresence across devices. Since its founding in 2005, Vidyo has raised $97 million in total capital.

Participated · Equity · May 2011

OrSense builds portable, non-invasive monitors for blood parameters including oxygen saturation, hemoglobin/hematocrit and glucose using its proprietary Occlusion Spectroscopy ring-shaped sensor. Its NBM 200MP received FDA clearance in 2010 for multi-parameter oximetry and the company has CE approval for its non-invasive hemoglobin monitor; a CE-approved glucose monitor was tested on over 450 diabetic subjects. The devices were tested on roughly 8,000 subjects across more than 40 clinical trials at over 20 sites worldwide. Customers include blood donation facilities, hospital departments, public screening programs and outpatient facilities. OrSense aims to expand commercialization into additional point-of-care segments such as women's health, public health programs and homecare and to extend its geographic reach beyond Europe into Asia Pacific, Africa and the Americas. Financially, the company closed an $18 million private financing to accelerate commercialization of its product portfolio.

Participated · Equity · Nov 2010

AeroScout builds Real‑Time Location System (RTLS) solutions that use Wi‑Fi RFID to provide real‑time visibility into the location, status and condition of mobile assets and people. Its technology lets customers leverage existing Wi‑Fi infrastructure instead of deploying separate proprietary networks for RTLS implementations. The company touts the invention of the world’s first Wi‑Fi‑based Active RFID tag and is recognized as a market leader by deployments and tags shipped. AeroScout serves more than 600 customers across healthcare, manufacturing, logistics and transportation. The firm plans to use new capital to support product development, sales and marketing. Headquartered in Redwood City, California, AeroScout also maintains offices in Europe, the Middle East, Asia, Australia and Latin America. AeroScout provides WiFi-based asset- and people-tracking solutions using Active RFID to locate and manage equipment and personnel. The company is based in San Mateo, California. It recently completed a third round of financing that the company says totaled $21 million. An earlier regulatory filing cited by PE Wire had reported $11.4 million of a $20.5M–$21M round before the company issued a correction. Investors in the round included Menlo Ventures (lead), Greylock Partners, Star Ventures, Pitango, Cisco Systems and Intel Capital. The article also notes the company had previously raised roughly $28.2 million since 1999.

Participated · Equity · May 2010

Sipera Systems provides comprehensive privacy, security and control across the range of enterprise Unified Communications (UC) applications, including VoIP, video, messaging, collaboration and others. Its product lineup includes smartphone UC security solutions and the UC-Sec enterprise UC security product family. The company focuses on securing the full spectrum of UC applications for enterprise customers. The recent capital infusion is intended to help advance its smartphone UC security offerings and further develop the UC-Sec product family. Management also plans to increase sales efforts in Asia, Europe and South America and to support an expanded reseller partner program. As of this announcement, Sipera has raised $48m in total funding to date.